Currently, an increasing number of reports show that Smad3 can promote invasion and metastasis by EMT in various cancers, such as lung adenocarcinoma, prostate cancer and pancreatic ductal adenocarcinoma34–36. Here, SMAD3 is linked to prostate cancer.